topic 17 Flashcards

1
Q

What are some general characteristics of hepatitis a virus? How is it transmitted? What is its epidemiology?

A

“infectious hepatitis”

  • Picornavirus:
  • Formal name is Enterovirus 7
  • Similar to Poliovirus or Rhinoviruses
  • Small, non-enveloped virion that is very environmentally stable
  • Transmission:
  • Fecal-oral
  • Frequently found in focal, common source outbreaks (contaminated food, etc.)

•Epidemiology:
•World-wide prevalence, especially in developing
countries
• Poor sanitation is the primary risk factor
• Responsible for ~30% of primary viral hepatitis infections in the USA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the genome structure of the hepatitis A virus and what are some characteristics of its replication cycle?

A
  • Genome Structure:
  • Single-stranded (+) polarity RNA genome
  • Replication:
  • Proteins are made by cleavage of a large polyprotein
  • HAV replicates with the standard cytoplasmic RNA-to-RNA mechanism employed by most single-stranded (+) polarity RNA viruses
  • Released from cells primarily by cytolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some clinical features of hep A and what are some prevention and therapy techniques?

A
  • Clinical features:
  • ~80% of adult infections are asymptomatic
  • Almost always asymptomatic in children
  • Causes mild hepatitis: self-limiting and acute (2-3 months, slow moving)
  • No chronic infection
  • Elicits life-long protective antibodies
  • Prevention and therapy:
  • Good sanitation is most effective
  • Immune seroglobin pre- or post-exposure is effective (passive immunity)
  • No antiviral therapy
  • Inactivated whole-virus vaccine is available
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some general characteristics of hepatitis b virus? How is it transmitted? What is its epidemiology?

A

“Serum hepatitis”

•Hepadnavirus:
• (HEPAtotropic DNA VIRUS)
• Small, enveloped virion
• Produces a large excess of subviral particles
containing viral surface proteins (HBsAgs)

  • Epidemiology:
  • Present world-wide, especially Asia, Sub-Saharan Africa, and the Amazon
  • Up to 10% of the people in high-endemic areas can be chronically infected
  • Less than 1% of US population is chronically infected
  • Accounts for about ~50% of primary viral hepatitis infections in the USA
  • Transmission:
  • Developed world: Primarily blood contact and sex
  • Developing world: Primarily vertical transmission from infected mothers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the genome structure of the hepatitis B virus and what are some characteristics of its replication cycle?

A

Genome structure is partially DS DNA. It is read in two different reading frames. Thus the same DNA is used to encode two different proteins. This leads to less mutations b/c a silent mutation in one reading frame could be missense in the other. It has to work for both.

Key things to remember:
•Replication is by error-prone reverse transcription
•Overlap of the S and P ORFs slows development of
drug resistance and vaccine escape
•Viral replication and release is non-cytopathic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are some clinical aspects of hepatitis B virus and what are some clinical outcomes? What is its pathogenesis?

A

•Disease:

  • Hepatitis (jaundice, abdominal pain, malaise…)
  • Acute infection
  • Symptoms appear 50-150 days post-infection
  • Recover is usually 2-3 months later
  • Chronic infection causes cirrhosis, liver failure, and hepatocellular carcinoma
  • Severity of disease varies widely
  • HBV causes ~50% of all HCC cases world-wide
  • > 90% of tumors carry random integrations of HBV DNA
  • ~50% of acute infections are asymptomatic, <0.1% are fatal
  • Disease usually gets worse with time during chronic infection (20+ years)
  • Severity of hepatitis during chronic infection is highly variable between patients
  • Recurrent “flares” of disease are common in an individual patient
  • Progression to chronicity is age dependent
  • ~90% of neonates will become chronically infected
  • ~5% of adults will become chronically infected
  • Up to 40% of male (spreads less in women) chronic carriers will die of complications of HBV infection
  • Pathogenesis:
  • Hepatitis B is an immune-mediated disease
  • Primarily caused by cytotoxic T-cells attacking infected hepatocytes
  • Cancer is caused by both chronic inflammation and viral factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is HBV diagnosed?

A

• The presence of an HBV infection and vaccination status can be characterized in a simple blood test that measures viral products and anti-
viral antibodies

  • HBsAg (surface glycoproteins) in serum correlates with viremia
  • anti-HBsAg antibodies without any other markers indicates vaccination
  • anti-HBsAg antibodies plus anti-HBeAg or anti-HBcAg (capside proteins) indicates a cleared infection
  • HBeAg (e-antigen) correlates with viremia
  • anti-HBeAg antibodies correlate with effective immune control of the virus (but not necessarily clearance)
  • the amount of HBV DNA in serum reveals the level of viremia
  • Anti-HBsAg is protective, anti-HBcAg and anti-HBeAg are not protective
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some ways to prevent and treat HBV?

A
  • Protection from blood contact (safe sex)
  • Vaccination (recombinant HBsAg) is highly effective and safe
  • Post-exposure prophylaxis is by concurrent HBIG (HBV immune globulin), and vaccination
  • Pegylated interferon A is approved, but it has serious side-effects and leads to long-term improvement for < 20% of chronic carriers
  • Entecovir and Tenofovir (nucleoside analog DNA chain terminators) are approved
  • They effectively suppress viral replication in most patients
  • Resistance usually develops patients treated with the older drugs
  • Viral replication rebounds after drug withdrawal
  • Therapy cures HBV infections in only 3-6% of patients even after years of treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are some general characteristics of HDV? What is its epidemiology?

A

Hepatitis D (Delta) Virus

  • Viroid-like Defective Virus:
  • Small enveloped virion
  • Parasite of HBV
  • Closest relative is the viroids of plants
  • Epidemiology:
  • World-wide prevalence
  • Found only where HBV is found, but not uniformly
  • Overall is much less common than HBV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the genome structure of HDV? How does it replicate?

A
  • Genome structure:
  • Small, single-stranded circular (-) polarity RNA genome
  • Encodes 1 protein, the delta antigen
  • Replication:
  • RNA to RNA replication, probably by host RNA Polymerase II
  • Intracellular replication is independent of HBV
  • Intercellular spread needs HBsAgs for envelope formation, so HDV cannot spread from cell to cell without HBV co-infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the disease and infection patterns of HDV?

A
  • Generally increases seerity of hepatitis in HBV patients
  • Superinfection of HBV asymptomatic carriers can activate hepatitis
  • Chronic infection is possible
  • Probably increases frequency of hepatocellular carcinoma in HBV+HDV chronically infected patients
  • Disease spectrum is the same as for HBV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you diagnosis, prevent and treat HDV?

A
  • Diagnosis
  • Detection of anti-delta antigen antibodies

•Prevention and therapy:

  • Prevent HBV infection
  • Vaccination
  • HBIG + vaccination for acute exposure
  • HBIG + vaccination is not prophylactic in chronic HBV carriers

•No antiviral therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are some general characteristics of HCV? What is its epidemiology? How is it transmitted?

A
  • Flavivirus:
  • Enveloped virus
  • Primary cause of viral non-A, non-B hepatitis
  • Epidemiology:
  • Present world-wide
  • Causes about 20% of the new viral hepatitis infections in US annually
  • Establishes chronic infection in 70-80% of primary infections
  • ~1.8% of US population is chronically infected •Rate is double in the African American population
  • Transmission:
  • Parenteral, primarily by direct blood contact
  • Sexual transmission is possible but very infrequent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the genome structure and replication of HCV?

A
  • Genome structure and genetics:
  • Uncapped single-stranded (+) polarity RNA
  • Highly genetically variable:
  • Six major genotypes
  • Encodes a large polyprotein
  • Genotype 1 causes ~70% of the cases in the USA

•Replication:

  • The viral RNA is translated independently of cap to make polyprotein
  • The RNA is replicated in cytoplasm by a viral RNA RNA polymerase
  • The polymerase is highly error-prone
  • This causes HCV to replicate as a quasispecies
  • New viruses are released without killing the cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are some mechanisms used by HCV to become highly persistent in their host? What is the ultimate clinical result of these factors?

A
  • Poor immune responses:
  • Slow, weak immune responses despite adequate antigen production
  • Successful resolution of infection does not necessarily give lasting protection (poor memory)
  • Immune Escape:
  • Evolution of humoral epitopes leads to evasion of antibodies
  • Evolution of CD8+ epitopes leads to escape from cell-mediated immunity
  • Immune Evasion:
  • Active suppression of immune system by viral proteins

Together, these problems have blocked all attempts to develop a vaccine to date

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is HCV disease like?

A
  • Acute hepatitis is mild and usually self-limiting
  • Most chronic carriers have mild liver damage

•About 20% of chronic carriers have progressive
hepatitis (very similar to HBV disease)

• Steatosis and insulin resistance are more common in HCV than HBV

•HCV-infected patients are hypersensitive to liver
damage from alcohol

•Kills 10-12,000 people per year in the USA

  • Chronic carriers are at high risk of fibrosis, cirrhosis, and hepatocellular carcinoma
  • HCV causes ~25% of HCC cases globally
17
Q

How is HCV diagnosed and how is it prevented?

A
  • Diagnosis:
  • Primary test is an ELISA to detect anti-HCV IgGs,
  • Tests for anti-HCV IgM are not available
  • Causes a long window between infection and serological detection
  • RT-PCR is used to measure HCV levels during therapy
  • Prevention:
  • Avoid blood contact
  • Using safer-sex practices may help
  • No vaccine is available
18
Q

How is HCV treated? What is its cure rate?

A
  • Current therapy is pegylated interferon alpha plus ribavirin plus telaprovir or boceprovir (NS3 protease inhibitors)
  • Cures ~75% of patients who can take it for 6 to 12 months
  • Is extremely difficult to administer due to complex dosing schedules
  • Has severe side effects
  • Peglylated interferon plus ribavirin plus sofosbuvir (a new NS3 inhibitor) was just approved
  • Cures 75-90% of patients after 3 to 6 months
  • Many other new drugs are in the pipeline
  • Cure rates as high as 100% have been reported in phase I trials of interferon-free drug combinations

HCV will be a routinely curable infection within a couple of years!